Beneficial effects of melatonin on prostanoids pathways in pulmonary hypertensive neonates

Figueroa, Esteban G.; Gonzaléz‐Candia, Alejandro; Villanueva, Cristian A.; Ebensperger, Germán; Reyes, Roberto V.; Llanos, Aníbal J.; Herrera, Emílio

doi:10.1016/j.vph.2021.106853

Cited by 9 publications

(7 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This translational study presented evidence to support the use of the postnatal melatonin treatment for arterial pulmonary hypertension of new-borns, providing a novel treatment option for babies suffering from chronic hypoxia related to cardiovascular diseases. Another recent study demonstrated that post-natal melatonin increased the activity and expression of vasodilating prostanoids in small pulmonary arteries, also supporting the use of melatonin for this condition [5].…”

mentioning

confidence: 76%

Melatonin and Related Compounds: Antioxidant and Anti-Inflammatory Actions

2022

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 76%

Melatonin and Related Compounds: Antioxidant and Anti-Inflammatory Actions

2022

View full text Add to dashboard Cite

show abstract

“…Melatonin, a neurohormone produced by the pineal gland, protects against ROS by direct scavenging of ROS, stimulation of antioxidant enzymes, and negative modulation of pro-oxidant agents [61,62]. Excessive ROS generation, the main cause of decreased vasodilator capacity and excessive proliferation of PASMCs, is associated with vascular dysfunction in PPHN.…”

Section: Melatoninmentioning

confidence: 99%

“…Studies have shown that in hypoxic models of PPHN, melatonin administration is effective in alleviating symptoms. Neonates are unable to produce melatonin, favoring ROS production in hypoxic conditions [62]. However, PPHN lambs treated with melatonin showed improved pulmonary vasodilation and decreased pulmonary arterial pressure, enhanced SOD and CAT expression, and decreased generation of superoxide anions and NADPH oxidases in RV [61,62].…”

Section: Melatoninmentioning

confidence: 99%

“…Neonates are unable to produce melatonin, favoring ROS production in hypoxic conditions [62]. However, PPHN lambs treated with melatonin showed improved pulmonary vasodilation and decreased pulmonary arterial pressure, enhanced SOD and CAT expression, and decreased generation of superoxide anions and NADPH oxidases in RV [61,62]. In a rat model of hypoxic PH melatonin was shown to attenuate pulmonary pressure and vascular remodeling, decreasing XO activity, MDA levels, NOX4 expression, and increasing CAT, GPx and SOD activities [63].…”

Section: Melatoninmentioning

confidence: 99%

See 1 more Smart Citation

Oxidative Stress and Antioxidant Therapy in Pulmonary Hypertension

et al. 2023

View full text Add to dashboard Cite

Pulmonary hypertension (PH) is a progressive disease characterized by elevated artery pressures and pulmonary vascular resistance. Underlying mechanisms comprise endothelial dysfunction, pulmonary artery remodeling and vasoconstriction. Several studies have shown evidence of the critical role of oxidative stress in PH pathophysiology. Alteration of redox homeostasis produces excessive generation of reactive oxygen species, inducing oxidative stress and the subsequent alteration of biological molecules. Exacerbations in oxidative stress production can lead to alterations in nitric oxide signaling pathways, contributing to the proliferation of pulmonary arterial endothelial cells and smooth muscle cells, inducing PH development. Recently, antioxidant therapy has been suggested as a novel therapeutic strategy for PH pathology. However, the favorable outcomes observed in preclinical studies have not been consistently reproduced in clinical practice. Therefore, targeting oxidative stress as a therapeutic intervention for PH is an area that is still being explored. This review summarizes the contribution of oxidative stress to the pathogenesis of the different types of PH and suggests antioxidant therapy as a promising strategy for PH treatment.

show abstract

“…Considering the great importance of melatonin in the synchronization of biorhythms of the cardiovascular system, the study of the effect of exogenously administered melatonin on systemic hemodynamic parameters in hypertensive patients is currently underway. Some studies show a direct vasodilating effect of melatonin (14,15), in others, it is mediated by pleiotropic, antioxidant action (16,17). Based on the foregoing, the prescription of an MT synthetic analog to patients with AH and insomnia, in addition to standard antihypertensive therapy at the disease onset, seems to be justified and promising.…”

Section: Introductionmentioning

confidence: 99%